Skip To Main Content
Srivani Venna on Muck Rack

Srivani Venna

Hyderabad
As seen in: MSN, Yahoo Finance, Yahoo, Verdict, GlobalData, Naval Technology, Railway Technology, Airport Technology, Power Technology, Airforce Technology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Srivani

Contact Srivani, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Orum to begin Phase I trial of ORM-1153 after FDA clearance

|
By Srivani Venna
| hospitalmanagement.net Verified
Orum’s first-in-human trial will target patients with AML and other haematologic malignancies. Credit: Ekahardiwito / Shutterstock.com. The US Food and Drug Administration (FDA) has approved Orum Therapeutics’ investigational new drug (IND) application for ORM-1153, a new cluster of differentiation 123-G1 to S phase transition protein 1 (CD123-GSPT1) degrader-antibody conjugate, enabling the start of a Phase I clinical trial.
Open in Who Shared View Duplicates (3) Issue with article?

Johnson & Johnson’s multiple myeloma treatment secures EC approval

|
By Srivani Venna
| hospitalmanagement.net Verified
The decision provides a new therapeutic option for patients with r/r MM. Credit: luchschenF / Shutterstock.com. The European Commission (EC) has approved an extended use of Johnson & Johnson’s Tecvayli (teclistamab), along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM). This decision provides a new therapeutic option for patients who have received at least one previous treatment.
Open in Who Shared View Duplicates (6) Issue with article?

Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation

|
By Srivani Venna
| Yahoo Verified
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation Mon, August 24, 2026 at 6:52 AM EDT Atrial fibrillation is characterised by an irregular heart rate. Credit: jittawit21 / Shutterstock.com. Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The ReVeRA-301 study has enrolled its first patient.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3,201 articles